Ligand Pharmaceuticals
LGND · Biotechnology
$303.53
1.4%Roivant Sciences
ROIV · Biotechnology
$36.49
2.6%The short version
- Ligand Pharmaceuticals is the larger business, with $268M of revenue in fiscal 2025 against $8.3M for Roivant Sciences, about 32 times as much.
- Ligand Pharmaceuticals grew revenue faster (60.4%, against −71.6%).
- Ligand Pharmaceuticals kept more of each dollar of sales as operating profit (15.3% operating margin, against −6,235.7% operating margin).
- Ligand Pharmaceuticals turned more of its sales into free cash flow (18.2% FCF margin, against −9,183.5% FCF margin).
- Ligand Pharmaceuticals earned a higher return on the capital invested in it (4.9%, against −62.6%).
| Latest fiscal year | LGND · FY25 | ROIV · FY25 |
|---|---|---|
| Size | ||
| Market cap | $6.6B | $26.3B |
| Revenue | $268M | $8.3M |
| Free cash flow | $48.9M | −$759M |
| Net income | $125M | −$300M |
| Growth | ||
| Revenue growth | 60.4% | −71.6% |
| 5-year growth | 10.4% | −19.0% |
| Share count change | 11.0% | −4.4% |
| Profitability | ||
| Gross margin | — | — |
| Operating margin | 15.3% | −6,235.7% |
| Net margin | 46.4% | −3,629.2% |
| FCF margin | 18.2% | −9,183.5% |
| Return on capital | 4.9% | −62.6% |
| Return on equity | 13.5% | −6.5% |
| Balance sheet | ||
| Net debt | −$287M | −$4.3B |
| Net debt / EBITDA | −3.8x | — |
| Dividends and buybacks | $15.0M | $0.0M |
| Valuation & quality | ||
| P/E | 32.3x | — |
| Piotroski F-score | 5 | 1 |
FY16
LGND $109M
ROIV —
FY17
LGND $141M
ROIV —
FY18
LGND $252M
ROIV —
FY19
LGND $120M
ROIV —
FY20
LGND $164M
ROIV $23.8M
FY21
LGND $242M
ROIV $55.3M
FY22
LGND $196M
ROIV $31.5M
FY23
LGND $131M
ROIV $32.7M
FY24
LGND $167M
ROIV $29.1M
FY25
LGND $268M
ROIV $8.3M
LGND
ROIV
FY16
LGND 40.3%
ROIV —
FY17
LGND 48.3%
ROIV —
FY18
LGND 65.1%
ROIV —
FY19
LGND 671.0%
ROIV —
FY20
LGND 22.9%
ROIV −4,500.5%
FY21
LGND 43.0%
ROIV −2,444.8%
FY22
LGND 1.6%
ROIV −2,875.9%
FY23
LGND 9.1%
ROIV 13,746.9%
FY24
LGND −13.5%
ROIV −3,453.3%
FY25
LGND 15.3%
ROIV −6,235.7%
LGND
ROIV
FY16
LGND $58.9M
ROIV —
FY17
LGND $86.4M
ROIV —
FY18
LGND $193M
ROIV —
FY19
LGND −$31.9M
ROIV —
FY20
LGND $50.1M
ROIV −$558M
FY21
LGND $70.0M
ROIV −$695M
FY22
LGND $120M
ROIV −$856M
FY23
LGND $46.1M
ROIV −$767M
FY24
LGND $95.2M
ROIV −$844M
FY25
LGND $48.9M
ROIV −$759M
LGND
ROIV
FY16
LGND —
ROIV —
FY17
LGND —
ROIV —
FY18
LGND 30.0%
ROIV —
FY19
LGND 156.4%
ROIV —
FY20
LGND 6.9%
ROIV —
FY21
LGND 13.4%
ROIV —
FY22
LGND 0.2%
ROIV −286.2%
FY23
LGND 2.0%
ROIV —
FY24
LGND −2.1%
ROIV —
FY25
LGND 4.9%
ROIV −62.6%
LGND
ROIV
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.